Welcome to our dedicated page for Tilray Brands news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on Tilray Brands stock.
Tilray Brands, Inc. (NASDAQ: TLRY) is a pioneering company in the field of medical and recreational cannabis production and research. Headquartered in Canada, Tilray has positioned itself as a global leader with a commitment to providing safe, consistent, and reliable therapy to patients and consumers worldwide. The company operates in multiple regions, including Canada, the United States, Europe, Australia, and Latin America, serving a diverse clientele ranging from patients and physicians to pharmacies, hospitals, and governments.
In 2021, Tilray underwent a significant transformation when legacy Aphria acquired legacy Tilray through a reverse merger, consolidating their strengths under the name Tilray Brands, Inc. This strategic merger expanded Tilray's market reach and product portfolio, bolstering its position in both the medical cannabis export market and the recreational cannabis sector.
Tilray's core offerings include a comprehensive range of cannabis products, from medical cannabis treatments to CBD products and alcoholic beverages. One of its latest ventures is the Ridge Runner West Coast IPA, a craft beer that has gained popularity for its complex flavors and craftsmanship. Additionally, Tilray's subsidiary, Widmer Brothers Brewing, recently launched a new Hefe Variety 12 Pack, showcasing innovative wheat beer styles.
The company is also making strides in the cannabis beverage market with the introduction of XMG Zero and XMG+ beverages. These products offer a variety of THC and CBG ratios, bringing unique flavors and high-quality ingredients to consumers across Canada.
Tilray's commitment to innovation extends beyond beverages. Solei, one of its wellness brands, has introduced the Warming Deep Tissue Stick, a cannabis-infused topical solution designed for active lifestyle enthusiasts. Meanwhile, Good Supply has released the Twisted All-in-One rechargeable vape, offering a potent and flavorful vaping experience.
Overall, Tilray Brands, Inc. continues to lead the way in cannabis research, cultivation, and distribution, with a diversified portfolio that caters to the needs of a global community. The company remains dedicated to enhancing the lives of its consumers through high-quality, innovative products that inspire well-being.
Tilray (NASDAQ: TLRY) has received approvals from New Zealand's Ministry of Health to launch its medical cannabis products nationwide. As a leading provider in Australia and New Zealand, Tilray aims to offer high-quality medical cannabis products, starting with its Purified CBD line. By Q2 2021, the company plans to expand its GMP-certified product range. Tilray collaborates with prominent research institutions to explore cannabis treatments for various health conditions. This expansion enhances patient access to medical cannabis in New Zealand.
Tilray, a global cannabis leader (Nasdaq: TLRY), announced its fiscal year 2020 and Q4 results, reporting a total revenue of $56.6 million, up 20.5% YoY, with cannabis revenue rising 46% to $41.2 million. The company achieved a net loss of $(3.0) million, significantly improved from $(219.8) million in Q4 2019. Adjusted EBITDA reached $2.2 million, marking a turnaround. Anticipating $100 million in synergies from its merger with Aphria, Tilray aims for enhanced market positioning. Cash reserves totaled $189.7 million, setting a solid foundation for future growth opportunities.
Tilray Inc. (TLRY), a leader in cannabis, will release its 2020 fiscal year and Q4 results on February 17, 2021, after market close. A conference call is scheduled for 5:00 p.m. ET, accessible via a U.S. toll-free number 877-407-0792, or internationally at 201-689-8263. The call will also be available through a live webcast on the Tilray website, which will later be archived for viewing.
Tilray Inc. (NASDAQ: TLRY) has partnered with Grow Pharma to import and distribute medical cannabis products in the UK. This agreement facilitates access for UK patients to GMP-certified medical cannabis solutions. Tilray plans to offer a range of products by March 2021, available through private practices or the NHS. According to CEO Brendan Kennedy, this partnership is a significant step in improving patient access in the UK, while Managing Director Sascha Mielcarek emphasizes the company's commitment to becoming a leading supplier as demand increases.
Tilray, a global leader in cannabis, announced its first export of GMP-certified medical cannabis from Portugal to Spain, in collaboration with Worldpharma Biotech. This shipment, approved by Spain's AEMPS, will support clinical trials for conditions such as Alzheimer's and Parkinson's. Tilray's pharmaceuticals-grade product is designed to meet stringent EU standards, enhancing patient access to reliable cannabis treatments. This milestone marks the 17th country receiving Tilray cannabis, showcasing its commitment to global medical cannabis standards.
Tilray, Inc. (NASDAQ: TLRY) has received market authorization from Infarmed in Portugal to offer its medical cannabis products, confirming compliance with strict quality and safety standards. This marks the first time a comprehensive quality dossier was required for market authorization in Europe. The approved products treat various conditions, including multiple sclerosis-related spasticity, severe seizure disorders, and chronic pain. With GMP certification, Tilray can manufacture and export medical cannabis products across the EU, catering to rising patient demand.
Tilray has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply GMP-certified medical cannabis products for experimentation in France. This initiative will last between 18 to 24 months, starting in Q1 2021, targeting patients with conditions like refractory neuropathic pain and drug-resistant epilepsy. Tilray's facility in Portugal will handle the production and export of these products. The announcement reflects Tilray's commitment to expanding operations in Europe and improving patient access to quality medical cannabis.
Tilray (Nasdaq: TLRY), a prominent player in the medical cannabis sector, has entered a co-promotion agreement with Hormosan, effective January 1, 2021. This collaboration aims to enhance marketing and sales for Tilray's full-spectrum cannabis extracts in Germany, leveraging Hormosan's expertise in pain therapy and neurology. Since launching its extracts in 2017, Tilray has expanded its offerings, which include various THC-CBD ratios, targeting chronic pain and sleep disorders. The partnership is expected to improve access for physicians and patients, ultimately benefiting patient care.
Tilray, a leader in cannabis research and distribution, has announced an agreement to exchange approximately $72.9 million in its 5.00% Convertible Senior Notes due 2023 for around 6.4 million shares of Class 2 common stock. This exchange, set to finalize by November 25, 2020, allows Tilray to reduce debt significantly and eliminate $3.6 million in annual interest costs. Post-transaction, about $277.9 million in Notes will remain outstanding. The shares from this exchange have not been registered under the Securities Act of 1933.
Tilray Inc. (Nasdaq: TLRY), a leader in cannabis cultivation and distribution, will announce its third-quarter results for the period ending September 30, 2020, on November 9, 2020, post-market close. A conference call will take place at 5:00 p.m. ET for investors, with dial-in options provided. The results will be discussed in detail during this call, and an archived webcast will be available on the company's website following the event. Tilray continues to serve thousands of patients across 15 countries globally.
FAQ
What is the current stock price of Tilray Brands (TLRY)?
What is the market cap of Tilray Brands (TLRY)?
What does Tilray Brands, Inc. do?
Where is Tilray Brands, Inc. headquartered?
What was the significance of the 2021 merger?
What are some of Tilray's wellness products?
What recent product has Tilray introduced in the beverage market?
What is the Ridge Runner West Coast IPA?
What vaping product has Good Supply recently launched?
What markets does Tilray operate in?
What is the mission of Tilray Brands, Inc.?
How does Tilray ensure the quality of its products?
